Organon (OGN) and ObsEva (OBSV) Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labo
Go back to Organon (OGN) and ObsEva (OBSV) Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labo| (NASDAQ: OBSV) | Delayed: 0.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.10 | 52 Week High | $ | |||
| Open | $0.10 | 52 Week Low | $ | |||
| Day High | $0.10 | P/E | N/A | |||
| Day Low | $0.10 | EPS | $ | |||
| Volume | 5,882 | |||||
| (NYSE: OGN) | Delayed: 18.42 -0.29 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.71 | 52 Week High | $8.00 | |||
| Open | $18.62 | 52 Week Low | $8.00 | |||
| Day High | $18.73 | P/E | N/A | |||
| Day Low | $18.20 | EPS | $0.00 | |||
| Volume | 1,541,861 | |||||
